Currently, treatment options for patients with peripheral spondyloarthritis, which includes psoriatic arthritis and non-psoriatic types, are limited. Philippe Carron, MD, Department of Rheumatology, Ghent University Hospital, Belgium, says, “One of the problems we encounter in the daily management of peripheral spondyloarthritis is that we have no other therapeutic options in patients refractory to NSAIDs [non-steroidal…
Scleroderma Autoantibodies Linked to Cancer Risk
Recent studies point to a relationship between scleroderma and autoantibodies (e.g., anti-RNA polymerase III or anti-RNPC3), and an increased cancer risk within a short interval of scleroderma onset. Mechanistic studies provide further evidence that cancer may trigger scleroderma in patients with these autoantibodies. However, many questions remain unanswered. A study in the Annals of the…
Anxiety Is an Independent Risk Factor for Bone Fractures
Higher anxiety levels in postmenopausal women may put them at increased risk of fracture and should be considered when assessing a woman’s risk of osteoporosis as well. This is the conclusion of a study recently published in the journal Menopause that looked at the role of anxiety in bone health.1 Specifically, the study examined the…
Interferon Score Predicts AI-CTDs
People with autoimmune connective tissue diseases produce antibodies against nuclear antigens up to 10 years before they develop clinical features. Anti-nuclear antibodies (ANAs) are also very common, and a small percentage of ANA-positive patients progress to clinical autoimmunity. The question: Is there a reliable way to screen at-risk patients before they develop active autoimmunity and…
New Joint Space Mapping Technique Doubles Diagnostic Sensitivity for Osteoarthritis
Traditional X-rays, move over—there may be a new gold standard for joint imaging to assess even the smallest changes that can signal the onset of arthritis, as reported recently in the journal Scientific Reports.1 Utilizing the combined expertise of radiologists, rheumatologists and engineers, University of Cambridge researchers developed an algorithm to monitor the joints of…
RA & Huntington’s Disease: New Epigenetic Technology Uncovers Overlap
Researchers working to decode the epigenetic landscape for rheumatoid arthritis (RA) were surprised to discover a connection to Huntington’s disease, a finding that could pave the way to discoveries of new therapeutic targets. By developing new methods to integrate data from epigenetic technologies, scientists at the University of California, San Diego (UCSD), set out to…
The Value of Repeat Antibody Testing in Lupus Patients
A recent study suggests costly antibody screening among patients with systemic lupus erythematosus could be reduced by limiting repeat screening of extractable nuclear antigens (ENAs). Researchers investigated how often results changed for anti-ENA and other commonly screened antibodies in repeat testing of patients with SLE. The findings were published in the Journal of Rheumatology.1 “We theorized,…
Lupus Nephritis Improvements: A 5-Decade Retrospective Review
The incidence of lupus nephritis in patients with systemic lupus erythematosus (SLE) has decreased over the past 50 years, according to a study from Gabriella Moroni, who works in the Nephrology Unit at Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico in Milano, Italy.1 Typically, renal involvement is part of the disease course for two-thirds of…
Is More Better? Weight Loss Analysis in Older Patients with Knee OA
Obesity is a modifiable risk factor for many patients with knee osteoarthritis (OA), and the National Institutes of Health recommend an initial weight loss goal of 10%. But how does losing more weight affect knee OA patients? In a new study, researchers compared the outcomes of knee OA patients who lost more and less than the recommended 10% of their baseline weight, finding significant improvement in health-related quality of life and reduction in pain for patients who lost twice what’s recommended…
Gene Therapy for OA
Background & objective: One of the major challenges in the treatment of chronic joint diseases, such as osteoarthritis (OA), is the need to provide sustained bioavailability of a therapeutic agent within the joint. Systemically administered drugs cannot sufficiently reach the synovial space, and intra-articularly injected agents are cleared from the joint fluid rapidly by the…
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 123
- Next Page »